Trial Profile

A non-interventional multicenter observational study assessing the safety and effectiveness of 8-week Glecaprevir/Pibrentasvir therapy in treatment naïve with compensated cirrhosis and with GT3 infection patients

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 23 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Jun 2022 Results of interim subanalysis of the ongoing, noninterventional, multicenter CREST study presented at The International Liver Congress 2022
26 Jun 2022 Results presented at The International Liver Congress 2022
11 May 2022 Results (n=386) published in the Advances in Therapy

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com